Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBIT (2016 - 2025)

Historic EBIT for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to $34.7 million.

  • Anaptysbio's EBIT rose 25249.81% to $34.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.7 million, marking a year-over-year increase of 8054.8%. This contributed to the annual value of -$114.9 million for FY2024, which is 3008.44% up from last year.
  • According to the latest figures from Q3 2025, Anaptysbio's EBIT is $34.7 million, which was up 25249.81% from -$26.2 million recorded in Q2 2025.
  • Anaptysbio's EBIT's 5-year high stood at $34.7 million during Q3 2025, with a 5-year trough of -$44.4 million in Q1 2023.
  • Its 5-year average for EBIT is -$24.8 million, with a median of -$27.8 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 511557.22% in 2022, then skyrocketed by 25249.81% in 2025.
  • Anaptysbio's EBIT (Quarter) stood at -$31.2 million in 2021, then grew by 16.64% to -$26.0 million in 2022, then crashed by 62.23% to -$42.1 million in 2023, then soared by 77.05% to -$9.7 million in 2024, then surged by 458.88% to $34.7 million in 2025.
  • Its EBIT was $34.7 million in Q3 2025, compared to -$26.2 million in Q2 2025 and -$27.5 million in Q1 2025.